DOCSLIB.ORG

Citations in Patient Blood Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Citations in Patient Blood Management Citations in Patient Blood Management James P. AuBuchon, MD, FCAP, FRCP(Edin) Bethesda, Maryland Copyright © 2014 by AABB. All rights reserved Other related publications available from the AABB: Getting Started in Patient Blood Management By James P. AuBuchon, MD, FCAP, FRCP(Edin); Kathleen Puca, MD, MT(ASCP)SBB, FCAP; Sunita Saxena, MD; Ira A. Shulman, MD; and Jonathan H. Waters, MD Standards for Perioperative Autologous Blood Collection and Administration, 4th edition Guidelines for Patient Blood Management and Blood Utilization Developed for the Clinical Transfusion Medicine Committee and the Transfusion Medicine Section Coordinating Committee by Joanne Becker, MD, and Beth Shaz, MD Blood Management: Options for Better Patient Care Edited by Jonathan H. Waters, MD The Transfusion Committee: Putting Patient Safety First, 2nd edition Edited by Sunita Saxena, MD Guidelines for Blood Recovery and Reinfusion in Surgery and Trauma Developed for the Scientific Section Coordinating Committee by Jonathan Waters, MD; Robert M. Dyga, RN, CCP; and Mark H. Yazer, MD, FRCP(C) Perioperative Blood Management: A Physician’s Handbook, 3rd edition Edited by Jonathan Waters, MD; Aryeh Shander, MD; and Karen King, MD Transfusion Medicine's Emerging Positions: Transfusion Safety Officers and Patient Blood Management Coordinators Edited by Susan T. Johnson, MSTM, MT(ASCP)SBB, and Kathleen E. Puca, MD, MT(ASCP)SBB Copyright © 2014 by AABB. All rights reserved Table of Contents Preface . vi Overview . 1 Program Management, Financial Implications, Cost-Effectiveness Analyses. 4 Anemia – Recognition and Management . 11 Use of Iron . 12 Use of Erythropoietin . 14 Utilization of Coagulation and Platelet Function Testing . 17 Indications, Utilizations, and Guidelines . 23 Red Blood Cells . 24 Frozen Plasma and Cryoprecipitate. 30 Platelets . 35 Peri-Surgical Interventions . 39 General Surgical Issues . 39 Preoperative Blood Collection and Acute Normovolemic Hemodilution. 43 Intra- and Postoperative Red Cell Recovery. 45 Issues Pertinent to Particular Disciplines . 53 Cardiology, Cardiac Surgery, Thoracic Surgery, and Vascular Surgery. 53 Critical Care . 71 Gastroenterology . 73 General Surgery . 74 Gynecology . 79 Hematology and Oncology. 80 Nephrology. 81 Obstetrics . 82 Orthopedics and Neurosurgery . 85 Oral/Facial Surgery and Otorhinolaryngology . 100 Pediatrics . 102 Transplantation . 109 Trauma and Massive Transfusion . 112 Urology . 118 Pharmacologic Interventions . 120 Measures to Reduce Blood Loss, Including Anticoagulation Reversal . 120 Effects of Antiplatelet Agents, Anticoagulation, and Hemodilution . 133 Copyright © 2014 by AABB. All rights reserved Preface Patient blood management (PBM), defined as an evidence-based, multi-disciplinary approach to optimizing the care of patients who might need transfusion, has continued to gain attention during the years since the publication of the previous list of Citations. The current compendium, including English articles listed in PubMed from January, 2010 through June, 2014, is indicative of the devel- opment of additional experience and knowledge in this important field of transfusion medicine. These are presented here to facilitate further dissemination of knowledge about the appropriate use of blood components and measures that can be implemented to avoid or delay the need for transfu- sion. The articles have been grouped according to the topics they explore. Many articles have been listed in two categories to facilitate their being found in a manual search. For example, an article on the use of tranxemic acid in arthroplasty would be listed in Pharmacologic Interventions: Measures to Reduce Blood Loss, Including Anticoagulation Reversal, as well as Issues Pertinent to Particular Disciplines: Orthopedics and Neurosurgery. However, the approach used by the compiler may not match the reader’s, and the use of electronic searching tools for keywords is encouraged to expand the number of citations identified. The compendium focuses on trials or reports of interventions to reduce the need for transfusion. Not all of the articles report decreased usage of transfusion, however, and careful reading of all papers of interest is advised. Not included are reports of the outcomes of transfusion per se, such as associating transfusion with poorer outcomes, or analyses of the effect of storage of blood compo- nents. Single case reports have also not been included. The compendium is intended to serve as a companion to the many educational publications, semi- nars and web-based sessions offered by AABB on the topic of PBM. Given the ongoing evolution of medical knowledge and scientific understanding, all readers are advised to search the most recently published literature to ensure application of the most current concepts. James P. AuBuchon, MD, FCAP, FRCP(Edin) Compiler Copyright © 2014 by AABB. All rights reserved OVERVIEW 1 Overview 1. Ansari S, Szallasi A. Blood management by transfusion triggers: When less is more. Blood Transfus 2012;10:28-33. 2. Barr PJ, Donnelly M, Cardwell CR, et al. The appropriateness of red blood cell use and the extent of overtransfusion: Right decision? Right amount? Transfusion 2011;51:1684-94. 3. Berger K, Klein HG, Seitz R, et al. The Wildbad Kreuth initiative: European current practices and recommendations for optimal use of blood components. Biologicals 2011;39:189-93. 4. Bidstrup BP. Blood transfusion: The epidemic continues. Eur J Cardiothorac Surg 2012;42: 120-1. 5. Bisbe E, Moltó L. Pillar 2: Minimising bleeding and blood loss. Best Pract Res Clin Anaesthe- siol 2013;27:99-110. 6. Blood: A precious resource. Lancet 2013;381:1789. 7. Branco BC, Inaba K, Doughty R, et al. The increasing burden of phlebotomy in the develop- ment of anaemia and need for blood transfusion amongst trauma patients. Injury 2012; 43:78-83. 8. Carson JL, Kuriyan M. What should trigger a transfusion? Transfusion 2010;50:2073-5. 9. Cottrell S, Davidson V. National audit of bedside transfusion practice. Nurs Stand 2013; 27:41-8. 10. Dalrymple K, Watson D. Ten years of transfusion practitioners and better blood transfusion in Scotland. Nurs Manag (Harrow) 2014;20:27-30. 11. Dutton RP. Resuscitative strategies to maintain homeostasis during damage control surgery. Br J Surg 2012;99(Suppl 1):21-8. 12. Engelbrecht S, Wood EM, Cole-Sinclair MF. Clinical transfusion practice update: Haemovig- ilance, complications, patient blood management and national standards. Med J Aust 2013;199:397-401. 13. Faraoni D, Willems A, Van der Linden P. Erythrocyte transfusion: A fair balance. Anesthesiol- ogy 2011;115:660-1. 14. Farrugia A, Vamvakas E. Toward a patient-based paradigm for blood transfusion. J Blood Med 2014;5:5-13. 15. Farrugia A. Falsification or paradigm shift? Toward a revision of the common sense of trans- fusion. Transfusion 2011;51:216-24. 16. Frank SM, Rothschild JA, Masear CG, et al. Optimizing preoperative blood ordering with data acquired from an anesthesia information management system. Anesthesiology 2013;118:1286-97. 17. Frank SM, Savage WJ, Rothschild JA, et al. Variability in blood and blood component utiliza- tion as assessed by an anesthesia information management system. Anesthesiology 2012;117:99-106. 18. Frank SM, Wick EC, Dezern AE, et al. Risk-adjusted clinical outcomes in patients enrolled in a bloodless program. Transfusion 2014 (in press). doi: 10.1111/trf.12752. Copyright © 2014 by AABB. All rights reserved 2 CITATIONS IN PATIENT BLOOD MANAGEMENT 19. Freedman J. The ONTraC Ontario program in blood conservation. Transfus Apher Sci 2014; 50:32-6. 20. Freedman J. Transfusion—whence and why. Transfus Apher Sci 2014;50:5-9. 21. Frellick M. Better blood management could be a boon for hospitals. Hosp Health Netw 2012;86:46-8. 22. Friedman MT. Blood transfusion practices: A little consistency please. Blood Transfus 2011;9:362-5. 23. Gammon HM, Waters JH, Watt A, et al. Developing performance measures for patient blood management. Transfusion 2011;51:2500-9. 24. Gohel MS, Bulbulia RA, Poskitt KR, Whyman MR. Avoiding blood transfusion in surgical patients (including Jehovah’s Witnesses). Ann R Coll Surg Engl 2011;93:429-31. 25. Gombotz H. Patient blood management: A patient-orientated approach to blood replace- ment with the goal of reducing anemia, blood loss and the need for blood transfusion in elec- tive surgery. Transfus Med Hemother 2012;39:67-72. 26. Goodnough LT, Levy JH, Murphy MF. Concepts of blood transfusion in adults. Lancet 2013;381:1845-54. 27. Goodnough LT, Shander A. Patient blood management. Anesthesiology 2012;116:1367-76. Erratum in: Anesthesiology 2013;118:224. 28. Graham J, Grant-Casey J, Alston R, et al. Assessing transfusion competency in junior doctors: A retrospective cohort study. Transfusion 2014;54:128-36. 29. Gross I, Shander A, Sweeney J. Patient blood management and outcome, too early or not? Best Pract Res Clin Anaesthesiol 2013;27:161-72. 30. Hare GM, Freedman J, David Mazer C. Review article: Risks of anemia and related manage- ment strategies: Can perioperative blood management improve patient safety? Can J Anaesth 2013;60:168-75. 31. Hofmann A, Farmer S, Shander A. Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. Oncologist 2011;16(Suppl 3):3-11. 32. Hofmann A, Farmer S, Towler SC. Strategies to preempt and reduce the use of blood prod- ucts: An Australian perspective. Curr Opin Anaesthesiol 2012;25:66-73. 33. Howie SR. Blood sample volumes in child health research: Review of safe limits. Bull World Health Organ 2011;89:46-53. 34. Isbister JP. The three-pillar matrix of patient blood management—an overview. Best Pract Res Clin Anaesthesiol 2013;27:69-84. 35. King R, Michelman M, Curran V, et al. Patient-centered approach to ensuring appropriate- ness of care through blood management. South Med J 2013;106:362-8. 36. Koh BC, Chong LL, Goh LG, et al for the Ministry of Health Clinical Practice Guidelines Workgroup on Clinical Blood Transfusion. Ministry of health clinical practice guidelines: Clinical blood transfusion. Singapore Med J 2011;52:209-18. 37. Kumar A, Figueroa PI, Gowans KL, et al. An evolution in blood management: Past, present, and future.
Load more

Recommended publications
  • Askari Bank Limited List of Shareholders (W/Out Cnic) As of December 31, 2017
    ASKARI BANK LIMITED LIST OF SHAREHOLDERS (W/OUT CNIC) AS OF DECEMBER 31, 2017 S. NO. FOLIO NO. NAME OF SHAREHOLDERS ADDRESSES OF THE SHAREHOLDERS NO. OF SHARES 1 9 MR. MOHAMMAD SAEED KHAN 65, SCHOOL ROAD, F-7/4, ISLAMABAD. 336 2 10 MR. SHAHID HAFIZ AZMI 17/1 6TH GIZRI LANE, DEFENCE HOUSING AUTHORITY, PHASE-4, KARACHI. 3280 3 15 MR. SALEEM MIAN 344/7, ROSHAN MANSION, THATHAI COMPOUND, M.A. JINNAH ROAD, KARACHI. 439 4 21 MS. HINA SHEHZAD C/O MUHAMMAD ASIF THE BUREWALA TEXTILE MILLS LTD 1ST FLOOR, DAWOOD CENTRE, M.T. KHAN ROAD, P.O. 10426, KARACHI. 470 5 42 MR. M. RAFIQUE B.R.1/27, 1ST FLOOR, JAFFRY CHOWK, KHARADHAR, KARACHI. 9382 6 49 MR. JAN MOHAMMED H.NO. M.B.6-1728/733, RASHIDABAD, BILDIA TOWN, MAHAJIR CAMP, KARACHI. 557 7 55 MR. RAFIQ UR REHMAN PSIB PRIVATE LIMITED, 17-B, PAK CHAMBERS, WEST WHARF ROAD, KARACHI. 305 8 57 MR. MUHAMMAD SHUAIB AKHUNZADA 262, SHAMI ROAD, PESHAWAR CANTT. 1919 9 64 MR. TAUHEED JAN ROOM NO.435, BLOCK-A, PAK SECRETARIAT, ISLAMABAD. 8530 10 66 MS. NAUREEN FAROOQ KHAN 90, MARGALA ROAD, F-8/2, ISLAMABAD. 5945 11 67 MR. ERSHAD AHMED JAN C/O BANK OF AMERICA, BLUE AREA, ISLAMABAD. 2878 12 68 MR. WASEEM AHMED HOUSE NO.485, STREET NO.17, CHAKLALA SCHEME-III, RAWALPINDI. 5945 13 71 MS. SHAMEEM QUAVI SIDDIQUI 112/1, 13TH STREET, PHASE-VI, DEFENCE HOUSING AUTHORITY, KARACHI-75500. 2695 14 74 MS. YAZDANI BEGUM HOUSE NO.A-75, BLOCK-13, GULSHAN-E-IQBAL, KARACHI.
    [Show full text]
  • Recombinant Factors for Hemostasis
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Chemical & Biomolecular Engineering Theses, Chemical and Biomolecular Engineering, Dissertations, & Student Research Department of Summer 2010 Recombinant Factors for Hemostasis Jennifer Calcaterra University of Nebraska at Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/chemengtheses Part of the Biochemical and Biomolecular Engineering Commons Calcaterra, Jennifer, "Recombinant Factors for Hemostasis" (2010). Chemical & Biomolecular Engineering Theses, Dissertations, & Student Research. 5. https://digitalcommons.unl.edu/chemengtheses/5 This Article is brought to you for free and open access by the Chemical and Biomolecular Engineering, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Chemical & Biomolecular Engineering Theses, Dissertations, & Student Research by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Recombinant Factors for Hemostasis by Jennifer Calcaterra A DISSERTATION Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Doctor of Philosophy Major: Interdepartmental Area of Engineering (Chemical & Biomolecular Engineering) Under the Supervision of Professor William H. Velander Lincoln, Nebraska August, 2010 Recombinant Factors for Hemostasis Jennifer Calcaterra, Ph.D. University of Nebraska, 2010 Adviser: William H. Velander Trauma deaths are a result of hemorrhage in 37% of civilians and 47% military personnel and are the primary cause of death for individuals under 44 years of age. Current techniques used to treat hemorrhage are inadequate for severe bleeding. Preliminary research indicates that fibrin sealants (FS) alone or in combination with a dressing may be more effective; however, it has not been economically feasible for widespread use because of prohibitive costs related to procuring the proteins.
    [Show full text]
  • A Study on Muslim Jarral Rajputs of Rajouri:A Review
    International Journal For Technological Research In Engineering Volume 6, Issue 10, June-2019 ISSN (Online): 2347 - 4718 A STUDY ON MUSLIM JARRAL RAJPUTS OF RAJOURI:A REVIEW Salma Shahzad1, Dr. Rama Singh2 Department of Sociology, Barkatullah University, Bhopal. M.P. Abstract: The present study is an attempt to explore the Srinagar Division and Kargil and Leh in Ladakh Region. The status of muslim jarral Rajputs hailing from Rajouri Siachen Glacier, although under Indian military control, does district, Jammu and Kashmir state. The state is divided into not lie under the administration of the state of Jammu and three sub-divisions i.e. Jammu, Srinagar (Kashmir) and Kashmir. Jammu and Kashmir have a Muslim majority Ladakh, mountain of Pir panjal range separates Jammu population. The population living in the Valley of Kashmir is region from Kashmir. Since time immemorial Rajouri was primarily homogeneous, despite the religious divide between the land of Rajas. Different Rajput Rajas in different times Muslims 94%, Hindus 4%, and Sikhs 2%, the state has large had ruled Rajouri and presently fairly a good number of communities of Buddhists Hindus (inclusive of Megh Rajputs are also settled in the vicinity of Rajouri. Rajputs Bhagats) and Sikhs. In Jammu, Hindus constitute 65% of the still enjoy high influence and reputation in socio-economic, population, Muslim 31% and Sikh 4%; in Ladakh, Buddhists cultural, political and traditional dominance etc., in the constitute about 46% of the population, the remaining being entire region. Jarral Rajputs claim their origin from the Muslims. The people of Ladakh are of Indo-Tibetan origin. Rajas of Rajouri; they are fairly widely distributed in the The total population of the Jammu and Kashmir according to region.
    [Show full text]
  • PERSONAL INFORMATION Francesco Rodeghiero WORK
    Curriculum Vitae PERSONAL INFORMATION Francesco Rodeghiero WORK EXPERIENCE February 2004- Present Scientific Director Fondazione Progetto Ematologia (Italy) August 2001-October 2015 Director of the Department of Cell Therapy and Hematology Azienda ULSS N.6 (Italy) <p>The Department includes a Unit for Bone Marrow Transplantation, a specialized Center for the diagnosis and treatment of Hemophilia and Thrombosis, and a Research Laboratory</p> 1989- 2016 Professor at the Postgraduate School of Hematology on a contract-basis University of Verona (Italy) February 1993-October 2015 Director of the Hematology Department Azienda ULSS N.6 (Italy) December 1985-October 2015 Director of the Hemostasis and Trombosis Center Azienda ULSS N.6 (Italy) September 2006-November 2016 Member; Chairman from June 2016 to November 2016 Ethics Committee on drugs research and investigational protocol studies of the Vicenza District (Italy) EDUCATION AND TRAINING July 1975- Degree in Medicine University School of Medicine (Italy) December 1984- Postgraduate specialization in Laboratory Medicine University of Padova (Italy) June 1981- Postgraduate specialization in Oncology University of Ferrara (Italy) July 1978- Postgraduate specialization in Hematology University of Ferrara (Italy) ADDITIONAL INFORMATION 15/12/2020 European Medicine Agency Page 1/46 Expertise He has been conducting clinical research in the fields of hematology and hemostasis since the early 1970s. His main interests include thrombocytopenia, hemophilia, von Willebrand disease, thrombophilia, acute promyelocytic leukemia, myeloma, policytemia vera, and the epidemiological aspects of haematological diseases. In the last decades he mainly devoted to clinical research in the field of ITP. Publications 1.T. Barbui, F. Rodeghiero, E. Dini The aspirin tolerance test in von Willebrands disease.
    [Show full text]
  • Download This PDF File
    Med J Chin PLA, Vol. 42, No. 12, December 1, 2017 ǂ1029 䃲eڝeᠳࢃ̺ ӵϔߙᡇ੢ϊҍᣴ໓͌ܠ੠ᣴ̹ࢴҝᣱ ͙఩ࡧጴࡻцᕑ䃶ܲц ᕑ᩽ࡧ႒̿͆ༀ঄цۇ͙఩Ϧℽ㼏ᩪ 䛹⫳ࡧ႒̿͆ༀ঄цۇ͙఩Ϧℽ㼏ᩪ ͙఩ࡧጴࡻцᕑ䃶ܲцᕑ䃶โ⻽̿͆ༀ঄ц 喞ᕑ᩽ٷ䩚䃹]Ȟ݇ѐ喞๝㵬ᕓнڟ] [͙పܲㆧण]ȞR605.97ȞȞȞȞ[᪳⡚ᴳᔃⴭ]ȞAȞȞȞȞ[᪳「㑂ण]Ȟ0577-7402(2017)12-1029-10 [DOI]Ȟ10.11855/j.issn.0577-7402.2017.12.02 Chinese emergency medicine expert consensus on diagnosis and treatment of traumatic hemorrhagic shock Emergency Medicine Branch of Chinese Medical Doctor Association People’s Liberation Army Professional Committee of Emergency Medicine People’s Liberation Army Professional Committee of Critical Care Medicine Professional Committee of Emergency Surgery, Emergency Medicine Branch of Chinese Medical Doctor Association 1ȞẮȞȞ䔜 ㏒10%⤯ڔѐ᭛ᠳᱦᷜ߇҈⩔κϦѿऺᝬ䕌᜼⮰ᱦѿ㏿ᲰႸ᪠ᕓ⮰ⵠ౻সߋ㘩䯈ⶹȠᢚWHO㐋䃍喏݇ 40ᆭБ̷Ϧ㓐⮰仂㺭₧ఌ[1]Ƞ⤯ڔ⮰₧ύস16%⮰㜠₷⫱ҷఌ݇ѐᝬ㜠喏सᬢ݇ѐ΋᭛ ᄽȟ㏰㏳╸∔̹䋟ȟ㏲㘊Џ䅎㈶Νসۻ᭛ᠳ݇ѐ䕌᜼ᱦѿ๓䛻๝㵬ᝬ㜠ᰵᩴᓖ⣛㵬䛻ٷѐ๝㵬ᕓн݇ ፤፤ऴᎢѺ㵬ࢷ(჆͵ͦᩢ㑕ࢷ┯90mmHg喏㘵ࢷ┯20mmHg喏ᝂ࣋ᰵ倄㵬ٷஔჄߋ㘩ःᢋ⮰⫱⤲⩋⤲䓳⼷Ƞн ࢷ㔱ᩢ㑕ࢷ㜖ദ㏫̷䭹Ĺ40mmHg)Ƞ30%~40%⮰݇ѐᗏ㔱₧ύ᭛ఌ๝㵬䓳ๆᝬ㜠喏ₐㆧᗏ㔱͙喏ᰵ̬䘔ܲ ఌͦ䩅䄛⮰᩽⇧᫥ᵴࣶ̹ᖜᑿ⮰⇧⫃ᣖ᫩㔸₧ύ喏ࢌ10%~20%Ƞᕑᕓ๝㵬᭛݇ѐ仂㺭⮰छ䶰䭞ᕓ₧ఌ[2-3]Ƞ ᄽๆஔჄߋ㘩䯈ⶹ㐨ऴᒭۻ䛹㺭喏छᰵᩴڟᄥκ͑䛹݇ѐᗏ㔱㜟ٷ㵬喏㏌₏๝㵬ᕓнܦࣶᬢȟᔗ䕋ᣓݢ (multiple organ dysfunction syndrome喏MODS)⮰ࣽ⩋喏䭹Ѻ₧ύ⢳Ƞ ⮰ᕑ䃶᩽ٷ䃲ᬔ౔㻰㠯স᣼倄݇ѐ๝㵬ᕓнڝᠳࢃȠ᱘ڟᕑ᩽⇧⮰Ⱔ㉓ٷⰚݹ᜽఩ᅆᬌ݇ѐ๝㵬ᕓн ⇧喏ͦᕑ䃶ࡧጴ᣼Ӈ䃶⫃ӉᢚȠ ⤲⩋⤲⫱⮰ٷ2Ȟ݇ѐ๝㵬ᕓн ᭛㵬ქ䛻̺㵬ネქ⼛⮰̹ࡥ䙹喏䕌᜼โঔ㏰㏳╸∔̹䋟喏Ϻ㔸ᑁٴ⮰⫱⤲⩋⤲ऄࡂ仂ٷѐ๝㵬ᕓн݇ 㘻ஔჄ⮰㐓ࣽᕓᢋჟȠڱ㵬䯈ⶹБࣶ܉䊣ᓚᓖ⣛ऄࡂȟ⅓Џ䅎ߔ߇႒ᐮ፤ȟ►⫳ࣹᏀȟ ᭛䛹㺭㘻ڢᰬᵥ᱘⮰⫱⤲⩋⤲ᩥऄ᭛๝㵬ᝬ㜠⮰ᓚᓖ⣛ߋ㘩䯈ⶹ喏ᅐٷ2.1Ȟᓚᓖ⣛ऄࡂȞ݇ѐ๝㵬ᕓн ၼὍᐻ(damage associatedܲڟϓ⩋ᢋѐⰤٷஔᓚᓖ⣛ᩥऄȠᄨ㜠ᓚᓖ⣛ߋ㘩䯈ⶹ⮰ͧ㺭ᱦݢ࠱᠘喝Ŗн Ꮐむࣶ๝ᣓᕓ►⫳ࣹᏀ喏ᑁ䊣㵬⫗ٹ㯷⮩স倄䓭⼧⢳᫻㯷⮩1㼒ࣽٷmolecular patterns喏DAMP)[4-5]喏ຮ☙н 㵬㈧܉⯚ᢋѐᑁ䊣ڱᄽ喏ᰬ㏴ᄨ㜠㏰㏳╸∔̹䋟ȟ㏲㘊㑦⅓喞ŗۻ⯚ᢋѐȟℇ㏲㵬ネ⍃␻ȟᓖ⣛ქ䛻ڱネ 㐋⓬≧ȟᓚ㵬ᴿᒎ᜼喏䭧ඊℇ㏲㵬ネࣶ㵬ネ㜾㑕ߋ㘩䯈ⶹ喏ߌ䛹㏰㏳㑦㵬㑦⅓喞Ř݇ѐᝬ㜠⮰ᠭ㐙ȟᑦ◴ ᓚᓖ⣛䯈ⶹȠޓߋ㘩喏ᄨ㜠ࣹᄰᕓ㵬ネ㜾㑕ߋ㘩㈶Ν喏ߌ⇸ܲڱ⮰ݦ⓬ᒝ৹⺊㏻ ⅓̺(ᗏ㔱ႄ౔⅓Џ䅎ߔ߇႒ᐮ፤喏࢟⅓ӇᏀ(DO2ٷ2.2Ȟ⅓Џߔ߇႒ᐮ፤ࣶ㏲㘊Џ䅎ᩥऄȞ݇ѐ๝㵬ᕓн
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,019,993 Bal (45) Date of Patent: Feb
    USOO6O19993A United States Patent (19) 11 Patent Number: 6,019,993 Bal (45) Date of Patent: Feb. 1, 2000 54) VIRUS-INACTIVATED 2-COMPONENT 56) References Cited FIBRIN GLUE FOREIGN PATENT DOCUMENTS 75 Inventor: Frederic Bal, Vienna, Austria O 116 263 1/1986 European Pat. Off.. O 339 607 4/1989 European Pat. Off.. 73 Assignee: Omrix Biopharmaceuticals S.A., O 534 178 3/1993 European Pat. Off.. Brussels, Belgium 2 201993 1/1972 Germany. 2 102 811 2/1983 United Kingdom. 21 Appl. No.: 08/530,167 PCTUS85O1695 9/1985 WIPO. PCTCH920.0036 2/1992 WIPO. 22 PCT Filed: Mar. 27, 1994 PCT/SE92/ 00441 6/1992 WIPO. 86 PCT No.: PCT/EP94/00966 PCTEP9301797 7/1993 WIPO. S371 Date: Nov.30, 1995 Primary Examiner-Carlos Azpuru Attorney, Agent, or Firm-Jacobson, Price, Holman, & S 102(e) Date: Nov.30, 1995 Stern, PLLC 87 PCT Pub. No.: WO94/22503 57 ABSTRACT PCT Pub. Date: Oct. 13, 1994 A two-component fibrin glue for human application includes 30 Foreign Application Priority Data a) a component A containing i) a virus-inactivated and concentrated cryoprecipitate that contains fibrinogen, and ii) Mar. 30, 1993 EP European Pat. Off. .............. 93105298 traneXamic acid or a pharmaceutically acceptable Salt, 51 Int. Cl." A61F 2/06; A61K 35/14 thereof, and b) component B containing a proteolytic 52 U s C - - - - - - - - - - - - - - - - - - - - - - - - - - -424/426. 530,380, 530/381: enzyme that, upon combination with component A, cleaves, O X O -- O - - - s 530(383. 530ass Specifically, fibrinogen present in the cryoprecipitate of 58) Field of Search 424/426,530,380 component A, thereby, effecting a fibrin polymer.
    [Show full text]
  • Urinary Trypsin Inhibitor: Miraculous Medicine in Many Surgical Situations?
    Korean J Anesthesiol 2010 Apr; 58(4): 325-327 Editorial DOI: 10.4097/kjae.2010.58.4.325 Urinary trypsin inhibitor: miraculous medicine in many surgical situations? Jong In Han Department of Anesthesiology and Pain Medicine, School of Medicine, Ewha Womans University, Seoul, Korea Recently, we encounter several articles regarding urinary Trypsin inhibitors act to suppress the proteolytic action trypsin inhibitor (UTI) published nationally [1,2]. When we take of trypsin on a variety of tissues and exert a localized anti- a glance at these articles, it feels like UTI acts as a miraculous inflammatory effect [8]. Therefore UTI is indicated for acute medicine on patients under general anesthesia because of inflammatory disorders, including acute pancreatitis, systemic its protection effect against surgical stress. Yet, even after the inflammatory reaction syndrome, circulatory insufficiency, first report on antitryptic action of urine by Bauer and Reich Stevens-Johnson syndrome, Toxic epidermal necrolysis (TEN), III in 1909 [3]; the start of use of the term UTI by Astrup and disseminated intravascular coagulation (DIC) and multiple Sterndorff in 1955 [4]; and numerous animal experiments and organ failure [9]. Previous studies of UTI have focused mainly clinical research done about UTI (803 articles about UTI and on modulating inflammatory reaction. UTI attenuates the 982 articles about ulinastatin in SCOPUS), UTI is not yet to elevation of neutrophil elastase release, thereby blunting the be used commonly. Therefore, it is important to understand rise of pro-inflammatory cytokine level; however, the actual the reason behind this situation. According to the webpage of mechanism in vivo is not clear [10].
    [Show full text]
  • Comparison of Fibrin Adhesives Prepared by 3 Different Methods
    Original Article Int. Arch. Otorhinolaryngol. 2013;17(1):62-65. DOI: 10.7162/S1809-97772013000100011 Comparison of fibrin adhesives prepared by 3 different methods Juliana Benthien Cavichiolo1, Maurício Buschle2, Bettina Carvalho3. 1) Medical Resident in Otolaryngology, HC-UFPR (Hospital de Clínicas da Universidade Federal do Paraná). 2) MMSc. Physician Assistant, Department of Otolaryngology, Faculty of Medicine, UFPR; Associate Professor of Otolaryngology. 3) Otolaryngologist by ABORLCCF. Institution: Hospital de Clínicas da Universidade Federal do Paraná. Curitiba / PR - Brazil. Mailing address: Juliana Benthien Cavichiolo - Rua General Carneiro, 181 - Alto da XV - Curitiba / PR - Brazil - Zip code: 80060-900 - E-mail: [email protected] Article received on May 1, 2011. Article accepted on October 25, 2012. SUMMARY Introduction: Fibrin tissue adhesive, which has applications in several areas of medicine, can be prepared by different methods. Aim: To compare fibrin tissue adhesives prepared by 3 different methods. Method: In this prospective experimental laboratory study, fibrin tissue adhesives prepared by the use of plasma fibrinogen (group 1), cryoprecipitation (group 2), and precipitation by ammonium sulfate (group 3) were tested on 15 rabbits and 10 fragments of dura mater. The quality of the clots was assessed in terms of the success of the healing process, local toxicity, graft adhesion capacity, and degree of adhesion of 2 fragments of dura mater produced. Results: All methods produced a clot with high adhesion and no toxicity, but tensile strength testing revealed that the glue produced from the ammonium sulfate-precipitated clot (group 3) was the strongest, requiring 39 g/cm ² to separate the fragments as opposed to 23 g/cm ² for group 2 and 13 g/cm ² for group 1.
    [Show full text]
  • Does Tranexamic Acid Stabilised Fibrin Support the Osteogenic Differentiation of Human Periosteum Derived Cells? J
    JEuropean Demol et Cells al. and Materials Vol. 21 2011 (pages 272-285) DOI: 10.22203/eCM.v021a21 Fibrin for osteogenic differentiation ISSN of1473-2262 hPDCs? DOES TRANEXAMIC ACID STABILISED FIBRIN SUPPORT THE OSTEOGENIC DIFFERENTIATION OF HUMAN PERIOSTEUM DERIVED CELLS? J. Demol1,3, J. Eyckmans2,3, S.J. Roberts2,3, F.P. Luyten2,3 and H. Van Oosterwyck1,3,* 1 Division of Biomechanics and Engineering Design, 2 Laboratory for Skeletal Development and Joint Disorders, 3 Prometheus, Division of Skeletal Tissue Engineering Leuven, K.U. Leuven, Leuven, Belgium Abstract Introduction Fibrin sealants have long been used as carrier for osteogenic Fibrin is a natural polymer that is formed during blood cells in bone regeneration. However, it has not been clotting from its precursor protein fibrinogen. The demonstrated whether fibrin’s role is limited to delivering conversion of fibrinogen to fibrin is triggered by thrombin cells to the bone defect or whether fibrin enhances (Blomback, 1996). In fibrin sealants, this coagulation osteogenesis. This study investigated fibrin’s influence on process has been engineered into an adhesive system that the behaviour of human periosteum-derived cells (hPDCs) is widely used in many surgical fields to promote when cultured in vitro under osteogenic conditions in two- haemostasis, sealing and tissue bonding. Commercial dimensional (fibrin substrate) and three-dimensional (fibrin fibrin sealant kits contain highly purified and virally carrier) environments. Tranexamic acid (TEA) was used inactivated human fibrinogen and human thrombin to reduce fibrin degradation after investigating its effect (Jackson, 2001). Fibrin is a non-cytotoxic, fully on hPDCs in monolayer culture on plastic. TEA did not resorbable, bioactive matrix with multiple interaction sites affect proliferation nor calcium deposition of hPDCs under for cells and other proteins (Mosesson et al., 2001).
    [Show full text]
  • A Study on Ulinastatin in Preventing Post ERCP Pancreatitis
    International Journal of Advances in Medicine Vedamanickam R et al. Int J Adv Med. 2017 Dec;4(6):1528-1531 http://www.ijmedicine.com pISSN 2349-3925 | eISSN 2349-3933 DOI: http://dx.doi.org/10.18203/2349-3933.ijam20175083 Original Research Article A study on ulinastatin in preventing post ERCP pancreatitis R. Vedamanickam1, Vinoth Kumar2*, Hariprasad2 1Department of Medicine, 2Department of Gasto and Hepatology , SREE Balaji Medical College and Hospital, Chrompet, Chennai, Tamil Nadu, India Received: 19 September 2017 Accepted: 25 October 2017 *Correspondence: Dr. Vinothkumar, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Pancreatitis remains the major complication of endoscopic retrograde cholangiopancreatography (ERCP), and hyperenzymemia after ERCP is common. Ulinastatin, a protease inhibitor, has proved effective in the treatment of acute pancreatitis. The aim of this study was to assess the efficacy of ulinastatin, compare to placebo study to assess the incidence of complication due to ERCPP procedure. Methods: In this study a randomized placebo controlled trial, patients undergoing the first ERCP was randomizing to receive ulinastatin one lakh units (or) placebo by intravenous infusion one hour before ERCP for ten minutes duration. Clinical evaluation, serum amylase, ware analysed before the procedure 4 hours and 24 hours after the procedure. Results: Total of 46 patients were enrolled (23 in ulinastatin and 23 in placebo group).
    [Show full text]
  • SAP American Society of Hematology Self-Assessment Program
    ASH®-SAP American Society of Hematology Self-Assessment Program SIXTH EDITION BK-ASH-SAP_6E-150511-FM.indd 1 4/29/2016 3:59:06 PM Disclosures As a provider accredited by the Accreditation Council for Hemostasis Research Society of North America (HTRS); Continuing Medical Education (ACCME), the American member of an advisory board for GlaxoSmithKline. Society of Hematology must ensure balance, independence, objectivity, and scientific rigor in all of the educational ac- Chapter 4, Hematopoietic growth factors tivities it sponsors. All authors are expected to disclose any financial relationships with any proprietary entity producing Aaron T. Gerds declares no competing financial interest. health care goods or services that have occurred within 24 Alan E. Lichtin declares no competing financial interest. months from the start of or during the production of the work and that are relevant to the author’s content. If an au- Chapter 5, Iron metabolism, iron overload, thor has such a financial interest, then she or he must dis- and the porphyrias close the name of the commercial interest and nature of the relationship (eg, consultant, grantee, etc.). An author who Heather A. Leitch has received honoraria, research funding, has no such financial relationship must declare that she or and/or served on advisory boards for Alexion, Apo-Pharma, he has nothing to disclose. The intent of this disclosure is Celgene, and Novartis. She is a member of the Exjade speak- not to prevent an author with a significant financial or other ers’ bureau. Jecko Thachil declares no competing financial relationship from making a presentation, but rather to pro- interest.
    [Show full text]
  • Pok News Digest a Monthly News Digest on Pakistan Occupied Kashmir
    POK NEWS DIGEST A MONTHLY NEWS DIGEST ON PAKISTAN OCCUPIED KASHMIR Volume 1 Number 5 October 2008 • Political Developments Conspiracy to Divide Gilgit Baltistan People Will Fail, Says GBUM Afghans to be Kicked Out of Gilgit Baltistan Kashmir Issue to be Finalized During Govt’s Tenure, Says Kaira MJC Condemns Zardari’s Statement on Kashmir • Economic Developments Line of Control Becomes Line of Commerce PoK Team Crosses Over, Hopes to Trade Peace Kohala Power Project Attracts Chinese Firm • International Developments EU Team Welcomes Reopening of Kashmir Trade Route Kashmir Solidarity Day Observed in Washington Compiled by Dr Priyanka Singh • Other Developments Kashmiris Observe 61st Founding Day Layout KIU Regional Campus in Baltistan Demanded Sanjay Kumar INSTITUTE FOR DEFENCE STUDIES AND ANALYSES No. 1, Development Enclave, Rao Tula Ram Marg October 2008 New Delhi-110 010 1 Jammu & Kashmir (Source: Based on the Survey of India Map, Govt of India 2000 ) October 2008 2 About this Issue One of the reports in this issue indicates that the PPP-led government in Pakistan intends to withdraw the Legal Framework Order of 2004 from Gilgit Baltistan and replace it with a new constitutional package which embodies an “AJK” like political set up for the Northern Areas- a set up which comprises a president, a cabinet headed by a prime minister and a High Court. The local PPP leadership in consultation with the establishment in Pakistan is reportedly working on finalities of political transition in the Northern Areas. On a positive note, at least the government of Pakistan has finally admitted that people in this region were subjected to deprivation from basic political rights and economic gains.
    [Show full text]